Clinical Trial Update: Cystatin C as an Early Marker of Contrast-Medium Nephropathy in Cardiac Catheterization Patients

View source ↗

Summary

Completed clinical trial evaluating whether cystatin C can serve as an early biomarker of contrast-induced nephropathy in patients undergoing cardiac catheteriz…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Contrast-induced Nephropathy
• Renal Failure

Snippet

Sponsor: National Heart Institute, Mexico | Conditions: Contrast Induced Nephropathy, Acute Renal Failure | Status: COMPLETED